Please assess the completion status of the following clinical trial:

Trial Title: Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Children eligible to be enrolled in the study were those~* whose parents provide written informed consent;~* were in generally good health based on the clinical judgment of the investigators;~* subjects were 22-45 months of age at the time of enrollment into V59P22E1;~* subject who had participated in the parent V59P22 study.~Exclusion Criteria:~Main exclusion criteria:~* Subjects with serious, acute, or chronic illnesses~* Subjects who had received any other licensed vaccines within 28 days (Exception: Influenza vaccine was allowed up to 14 days prior to and no less than 14 days after the study immunization) prior to enrolment and any study visit~* Subjects who had received any Meningococcal vaccine since the study dose of MenACWY or Men C at 12 months of age in V59P22 trial.

- Gender: ALL
- Minimum Age: 22 Months
- Maximum Age: 45 Months
- Healthy Volunteers: f

Study Arms:
- MenACWY (2 primary + 1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
- MenACWY (1 primary + 1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
- MenC (1 primary dose)+MenACWY (1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).